In contrast to parental cells, chronic-treated BRAF-inhibitor resistant melanoma cell lines did not decrease phospho-ERK1/2 or phospho-S6 levels when subjected to BRAF inhibitor (Supplementary Fig. 1a). This evidence concerns the gene MAPK3 and melanoma.